Skip to main content
Clinical Trials/NCT02080936
NCT02080936CompletedNot Applicable

Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD

5 Santé1 site in 1 country138 target enrollmentStarted: January 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
138
Locations
1
Primary Endpoint
Muscle wasting in COPD patient

Study Overview

Brief Summary

Peripheral muscle mass and strength are relevant indicators of COPD survival. Current guidelines recommend to assess muscle strength only in muscle wasted patients. However, a recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp. Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of muscle wasting clinical signs.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients who have got FFMI (bioimpedance)
  • •Patients who have done quadriceps muscle strenght evaluation

Exclusion Criteria

  • •Patients without FFMI
  • •Patients without quadriceps muscle strenght

Outcomes

Primary Outcomes

Muscle wasting in COPD patient

Time Frame: baseline

Secondary Outcomes

  • Muscle weakness in COPD patient(baseline)

Investigators

Sponsor
5 Santé
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials